Boston Sci In China: Investment Chases Big Growth
This article was originally published in The Gray Sheet
While Boston Scientific’s core cardiology business units continue to face steep growth challenges in the U.S, China’s massive population remains essentially an untapped market.
You may also be interested in...
The cuts expand on a 2011 restructuring plan, with hopes of reducing operating expenses by up to $375 million at the end of 2013.
Move will realign four product divisions into two new operating units to support growth opportunities, help offset impact of 2.3% device tax set to take effect next year.
Consensus document issued on transcatheter heart valves. Boston Scientific launches Asia-Pacific organization. More news briefs.